tert-butyl 3-(6-{2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethoxy}pyridin-3-yl)-L-alaninate | 959993-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 3-(6-{2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethoxy}pyridin-3-yl)-L-alaninate
• 英文别名: tert-butyl (2S)-2-amino-3-[6-[2-[8-[(4-methoxyphenyl)methyl]-6,7-dihydro-5H-1,8-naphthyridin-2-yl]ethoxy]pyridin-3-yl]propanoate
• CAS: 959993-31-8
• 化学式: C₃₀H₃₈N₄O₄
• 分子量: 518.656
• InChiKey: NVEQLTVZGVQUID-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  99.8
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-氯噻吩-2-羧酸 、 tert-butyl 3-(6-{2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethoxy}pyridin-3-yl)-L-alaninate 在 2-羟基吡啶-N-氧化物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  WO2008/93065

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl N-[(benzyloxy)carbonyl]-3-(6-{2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethoxy}pyridin-3-yl)-L-alaninate 在 钯 氢气 、 silica gel 、 四氢呋喃 、 二氯甲烷 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 以to afford tert-butyl 3-(6-{2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethoxy}pyridin-3-yl)-L-alaninate (536 mg, 92%)的产率得到tert-butyl 3-(6-{2-[8-(4-methoxybenzyl)-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl]ethoxy}pyridin-3-yl)-L-alaninate
  参考文献：
  名称：

  PHENYLALANINE DERIVATIVES

  摘要：

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有其作为活性成分的制药组合物，以及它们作为药物在温血动物（如人类）中治疗具有明显血管生成或血管成分的疾病，例如固体肿瘤的制药用途。本发明还涉及a5b1拮抗剂，其还表现出对其他整合素的适当选择性特征。

  公开号：

  US20080045521A1

文献信息

• PHENYLALANINE DERIVATIVES
  申请人：Arnould Jean-Claude

  公开号：US20080045521A1

  公开（公告）日：2008-02-21

  The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有其作为活性成分的制药组合物，以及它们作为药物在温血动物（如人类）中治疗具有明显血管生成或血管成分的疾病，例如固体肿瘤的制药用途。本发明还涉及a5b1拮抗剂，其还表现出对其他整合素的适当选择性特征。
• L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
  申请人：Arnould Jean-Claude

  公开号：US20090062267A1

  公开（公告）日：2009-03-05

  The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备方法，含有其作为活性成分的药物组合物，以及它们作为药物用于治疗具有重要血管生成或血管成分的疾病，例如固体肿瘤的治疗，用于制造药物。本发明还涉及抑制a5b1的化合物，并且还表现出适当的选择性谱以对抗其他整合素。
• N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS
  申请人：Astra Zeneca AB

  公开号：EP2049490A1

  公开（公告）日：2009-04-22
• [EN] N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS<br/>[FR] DÉRIVÉS DE PHÉNYLALANINE
  申请人：ASTRAZENECA AB

  公开号：WO2007141473A1

  公开（公告）日：2007-12-13

  [EN] The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.
  [FR] La présente invention concerne des composés qui inhibent la fonction de a5b1, des procédés pour leur préparation, des compositions pharmaceutiques contenant ceux-ci en tant qu'ingrédient actif, leur utilisation en tant que médicaments et leur utilisation dans la fabrication de médicaments pour utilisation dans le traitement chez des animaux à sang chaud tels que des humains de maladies qui ont une angiogenèse significative de composant vasculaire tel que pour le traitement de tumeurs solides. La présente invention concerne en outre des antagonistes de a5b1 qui présentent en outre des profil(s) de sélectivité appropriés contre d'autres intégrines.
• [EN] L-ALANINE DERIVATIVES AS a5ßL ANTAGONISTS<br/>[FR] DÉRIVÉS DE L-ALANINE UTILISÉS COMME ANTAGONISTES D'ALPHA-5 BÊTA-L
  申请人：ASTRAZENECA AB

  公开号：WO2008093065A1

  公开（公告）日：2008-08-07

  [EN] The present invention relates to compounds of the formula (I) that inhibit of a5bl function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid rumours. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins.
  [FR] La présente invention concerne des composés de formule (I) qui inhibent la fonction de a5bl, des procédés pour les préparer, des compositions pharmaceutiques les contenant en tant qu'ingrédient actif, leur utilisation en tant que médicaments et leur utilisation dans la fabrication de médicaments destinés, chez des animaux à sang chaud, par exemple les êtres humains, au traitement de maladies comportant une composante vasculaire ou d'angiogenèse significative, par exemple pour le traitement de tumeurs solides. La présente invention concerne également des composés qui inhibent a5bl, et qui présentent en outre un ou des profils de sélectivité appropriés contre d'autres intégrines.